CN120114618A - 用于治疗阿尔茨海默病和其他神经退行性病症的逆转运复合体的稳定化 - Google Patents

用于治疗阿尔茨海默病和其他神经退行性病症的逆转运复合体的稳定化 Download PDF

Info

Publication number
CN120114618A
CN120114618A CN202510180683.1A CN202510180683A CN120114618A CN 120114618 A CN120114618 A CN 120114618A CN 202510180683 A CN202510180683 A CN 202510180683A CN 120114618 A CN120114618 A CN 120114618A
Authority
CN
China
Prior art keywords
vps35
nucleic acid
core protein
vps26a
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202510180683.1A
Other languages
English (en)
Chinese (zh)
Inventor
S·A·斯莫尔
G·佩茨科
Y·H·库雷什
S·D·瓦克萨尔
A·福布斯
R·考克斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meragutex Uk No 2 Co ltd
Columbia University
Cornell University
Original Assignee
Meragutex Uk No 2 Co ltd
Columbia University
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meragutex Uk No 2 Co ltd, Columbia University, Cornell University filed Critical Meragutex Uk No 2 Co ltd
Publication of CN120114618A publication Critical patent/CN120114618A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/40—Vector systems having a special element relevant for transcription being an insulator
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202510180683.1A 2019-12-05 2020-12-07 用于治疗阿尔茨海默病和其他神经退行性病症的逆转运复合体的稳定化 Pending CN120114618A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962943999P 2019-12-05 2019-12-05
US62/943,999 2019-12-05
US202063074578P 2020-09-04 2020-09-04
US63/074,578 2020-09-04
CN202080093935.2A CN115297891A (zh) 2019-12-05 2020-12-07 用于治疗阿尔茨海默病和其他神经退行性病症的逆转运复合体的稳定化
PCT/US2020/063627 WO2021113824A1 (en) 2019-12-05 2020-12-07 Stabilization of retromer for the treatment of alzheimer's disease and other neurodegenerative disorders

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202080093935.2A Division CN115297891A (zh) 2019-12-05 2020-12-07 用于治疗阿尔茨海默病和其他神经退行性病症的逆转运复合体的稳定化

Publications (1)

Publication Number Publication Date
CN120114618A true CN120114618A (zh) 2025-06-10

Family

ID=76222705

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202510180683.1A Pending CN120114618A (zh) 2019-12-05 2020-12-07 用于治疗阿尔茨海默病和其他神经退行性病症的逆转运复合体的稳定化
CN202080093935.2A Pending CN115297891A (zh) 2019-12-05 2020-12-07 用于治疗阿尔茨海默病和其他神经退行性病症的逆转运复合体的稳定化

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202080093935.2A Pending CN115297891A (zh) 2019-12-05 2020-12-07 用于治疗阿尔茨海默病和其他神经退行性病症的逆转运复合体的稳定化

Country Status (12)

Country Link
US (1) US20230021959A1 (cg-RX-API-DMAC7.html)
EP (1) EP4069315A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023505271A (cg-RX-API-DMAC7.html)
KR (1) KR20220152192A (cg-RX-API-DMAC7.html)
CN (2) CN120114618A (cg-RX-API-DMAC7.html)
AU (1) AU2020395327A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022011073A2 (cg-RX-API-DMAC7.html)
CA (1) CA3160785A1 (cg-RX-API-DMAC7.html)
IL (1) IL293599A (cg-RX-API-DMAC7.html)
MX (1) MX2022006895A (cg-RX-API-DMAC7.html)
PH (1) PH12022551373A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021113824A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023003655A (es) 2020-09-29 2023-06-22 Neuexcell Therapeutics Inc Vector neurod1.
US20250161243A1 (en) * 2022-02-21 2025-05-22 The Scripps Research Institute Mef2 transcriptional activators to treat neurologic conditions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007047796A2 (en) * 2005-10-17 2007-04-26 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
US20080214482A1 (en) * 2005-11-15 2008-09-04 Scott Small Retromer-based assays and methods for treating alzheimer's disease
WO2009108274A2 (en) * 2008-02-26 2009-09-03 The University Of North Carolina At Chapel Hill Methods and compositions for adeno-associated virus (aav) with hi loop mutations
EP2607900A1 (de) * 2011-12-22 2013-06-26 Protagen AG Markersequenzen für Brustkrebs und deren Verwendung
BR112014020325A2 (pt) * 2012-02-17 2017-08-08 Childrens Hospital Philadelphia composições de vetor do aav e métodos para a transferência de gene para as células, órgãos e tecidos
US20160250182A1 (en) * 2013-01-11 2016-09-01 The Trustees Of Columbia University In The City Of Rab7l1 interacts with lrrk2 to modify intraneuronal protein sorting and parkinson's disease risk
WO2014110481A2 (en) * 2013-01-11 2014-07-17 The Trustees Of Columbia University In The City Of New York Rab7l1 interacts with lrrk2 to modify intraneuronal protein sorting and parkinson' s disease risk
GB201409519D0 (en) * 2014-05-29 2014-07-16 Univ Leicester Senescent cell biomarkers
AU2016324317A1 (en) * 2015-09-17 2018-03-08 Coda Biotherapeutics, Inc. Compositions and methods for treating neurological disorders
WO2017191274A2 (en) * 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein
WO2018112446A2 (en) * 2016-12-18 2018-06-21 Selonterra, Inc. Use of apoe4 motif-mediated genes for diagnosis and treatment of alzheimer's disease
EP3692158A4 (en) * 2017-10-03 2021-08-04 Prevail Therapeutics, Inc. GENE THERAPIES FOR LYSOSOMAL DISEASES
US20190345516A1 (en) * 2018-03-12 2019-11-14 Musc Foundation For Research Development Methods for treating eye disease

Also Published As

Publication number Publication date
EP4069315A1 (en) 2022-10-12
IL293599A (en) 2022-08-01
EP4069315A4 (en) 2024-03-20
KR20220152192A (ko) 2022-11-15
CN115297891A (zh) 2022-11-04
JP2023505271A (ja) 2023-02-08
CA3160785A1 (en) 2021-06-10
AU2020395327A1 (en) 2022-07-21
JP2025149978A (ja) 2025-10-08
PH12022551373A1 (en) 2023-05-08
WO2021113824A1 (en) 2021-06-10
US20230021959A1 (en) 2023-01-26
BR112022011073A2 (pt) 2022-09-20
MX2022006895A (es) 2022-11-09

Similar Documents

Publication Publication Date Title
AU2017250756B2 (en) Adeno-associated virus vector delivery of B-sarcoglycan and microRNA-29 and the treatment of muscular dystrophy
US12428653B2 (en) Gene therapy for ceroid lipofuscinoses
US12454702B2 (en) Minigene therapy
ES3061210T3 (en) Gene therapy for ocular disorders
JP7384797B2 (ja) ムコ多糖症iiib型のための遺伝子療法
EP4049683A1 (en) Evasion of neutralizing antibodies by a recombinant adeno-associated virus
US20230174994A1 (en) Engineered parkin and uses thereof
US20210371480A1 (en) Compositions and methods for treating age-related macular degeneration and other diseases
US20230104357A1 (en) Combination of Retromer Pharmacological Chaperones and Exogenous Retromer for the Treatment of Alzheimer's Disease and Other Neurodegenerative Diseases and Disorders
JP2025149978A (ja) アルツハイマー病および他の神経変性障害の処置のためのレトロマーの安定化
US20240415983A1 (en) Aav-mediated therapies for vision loss associated with friedreich’s ataxia
US20220226507A1 (en) Optimized gene therapy targeting retinal cells
US20210207168A1 (en) Aav-compatible laminin-linker polymerization proteins
IL294924A (en) Useful preparations for the treatment of gm1 gangliosidosis
WO2024178364A1 (en) Gene therapy for treatment of pain
US20230414785A1 (en) Compositions and uses thereof for treatment of angelman syndrome
US20250186621A1 (en) Materials and methods for the treatment of eif2b5 mutations and diseases resulting therefrom
US20240189452A1 (en) Recombinant Adeno-Associated Virus Encoding Methyl-CPG Binding Protein 2 for Treating PITT Hopkins Syndrome VIA Intrathecal Delivery
US20250152740A1 (en) Materials and methods for the treatment of limb girdle muscular dystrophy
HK40077196A (en) Evasion of neutralizing antibodies by a recombinant adeno-associated virus

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination